Press Releases DURECT Corporation

Equities

DRRX

US2666055007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.9313 ^USD	+1.68%		+6.90%	+57.85%

Mar. 27	Transcript : DURECT Corporation, Q4 2023 Earnings Call, Mar 27, 2024
Mar. 27	DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Durect: Q4 Earnings Snapshot	Mar. 27	AQ
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 27	PR
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	Mar. 20	PR
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada	Mar. 04	PR
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 07	PR
Durect: Q3 Earnings Snapshot	Nov. 13	AQ
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update	Nov. 13	PR
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update	Nov. 09	PR
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality	Nov. 07	PR
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis	23-09-07	PR
DURECT Corporation Announces Presentations in Upcoming Investor Conferences	23-08-31	PR
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update	23-08-10	AQ
Durect: Q2 Earnings Snapshot	23-08-09	AQ
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update	23-08-03	PR
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	23-07-20	PR
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis	23-06-07	PR
DURECT CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-05-16	AQ
Durect: Q1 Earnings Snapshot	23-05-08	AQ
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8	23-05-01	PR
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis	23-04-27	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases DURECT Corporation

Equities

DRRX

US2666055007

Press Releases

Filters